| Literature DB >> 28428631 |
Ying Jie Ma1, Bok Luel Lee2, Peter Garred1.
Abstract
The complement system is an innate immune defense machinery comprising components that deploy rapid immune responses and provide efficient protection against foreign invaders and unwanted host elements. The complement system is activated upon recognition of pathogenic microorganisms or altered self-cells by exclusive pattern recognition molecules (PRMs), such as collectins, ficolins and pentraxins. Recent accumulating evidence shows that the different classes of effector PRMs build up a co-operative network and exert synergistic effects on complement activation. In this review, we describe our updated view of the crosstalk between previously unlinked PRMs in complement activation and the potential pathogenic effects during infection and inflammation.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28428631 PMCID: PMC6130212 DOI: 10.1038/emm.2017.51
Source DB: PubMed Journal: Exp Mol Med ISSN: 1226-3613 Impact factor: 8.718
Figure 1General view of complement activation. The complement system comprises the following three activation pathways: the classical, lectin and alternative pathways. The classical pathway is activated when the C1 complex (the molar ratio of C1q, C1r and C1s, 1:2:2) binds immunoglobulins (mainly IgG clusters) that recognize pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs). Activation of the lectin pathway is induced by PRMs, such as mannose-binding lectin, ficolins (ficolin-1, -2 or -3) or collectins (collectin-10 or collectin-11), upon binding to PAMPs or DAMPs. The lectin pathway-initiating PRMs are found in complexes with LP-associated serine proteases (MASPs), whereas C1q is found in complexes with the serine proteases C1r and C1s. Activation of the classical and lectin pathways leads to cleavage of C4 and C2, and the formation of a C3 convertase (C4b•C2a). Initiation of the alternative pathway occurs by spontaneous hydrolysis of C3 in solution. Activated C3 leads to formation of the initial C3b, which covalently bind to target surfaces. Surface-bound C3b allows factor B (fB) to bind. fB is then cleaved by the enzyme factor D (fD), leading to the formation of the alternative C3 convertase (C3b•Bb). The alternative C3 convertase is stabilized by the plasma protein properdin. The C3 convertases cleave C3 into the opsonin C3b and the anaphylatoxin C3a. Activation of C3 also leads to the formation of the classical and lectin pathway C5 convertase (C3b•C4b•C2a) and the alternative C5 convertase (C3b·Bb·C3b). C5 convertase cleaves C5 into the anaphylatoxins C5a and C5b. Deposition of C5b onto a target initiates formation of the membrane attack complex (C5b-9, MAC) in the late steps and leads to lysis of the target. The alternative pathway also works as an amplification loop for the classical and lectin pathways.
Crosstalk of soluble PRMs involved in pattern recognition and complement activation
| Ficolin-1:PTX3 | Clearance of dying host cells; modulation of inflammatory cytokine secretion; LP activation | [ |
| Ficolin-2:PTX3 | Expansion of pattern recognition and complement amplification | [ |
| MBL:PTX3 | Enhancement of opsonophagocytosis and amplification of complement activation via CP:LP crosstalk | [ |
| C1q:PTX3 | CP activation; inhibition upon occurrence in fluid phage | [ |
| CL-12:properdin | AP activation | [ |
| CL-12:CRP | CP activation | [ |
| Ficolin-1:CRP | Modulation of inflammatory cytokine secretion via GPCR43 during infection | [ |
| Ficolin-2:CRP | Cross-activation of CP and LP and complement amplification | [ |
| C1q:CRP | CP activation or inhibition on surfaces upon occurrence in fluid phase | [ |
| C1q:SAP | CP activation | [ |
Abbreviations: AP, alternative pathway; CP, classical pathway; CRP, C-reactive protein; GPCR43, G-protein-coupled receptor 43; LP, lectin pathway; PTX, pentraxin; SAP, serum amyloid P component.
Figure 2An expanded network of complement activation by previously unlinked PRMs. The model reevaluates the classical view of complement activation that is mediated exclusively via complement PRMs and highlights the synergistic effects of complement PRMs on complement-mediated immune responses. The classical pathway (CP) is mainly activated in an antibody-dependent manner by IgG clusters (or IgM) but is also initiated through pentraxins, such as PTX3, C-reactive protein (CRP) and serum amyloid P component (SAP), via C1q. In addition, surface-bound collectin-12 (CL-12) is hypothesized to mediate CP activation by crosstalk with CRP. Activation of the lectin pathway (LP) is induced directly by mannose-binding lectin (MBL), ficolins and collectins but can also be mediated by MBL or ficolins through PTX3, CRP or SAP. Moreover, the CP and LP are capable of being cross-activated through formation of heterocomplexes between PTX3 (or CRP) and MBL (or ficolin-2) and C1q. The cross-activation comprises two amplification pathways: target→PTX3 (or CRP)→ficolin-2/MASPs→C4→C3→formation of the membrane attack complex (MAC; amplification 1); target→MBL (or ficolin-2/MASPs)→PTX3 (or CRP) →C1q→C4→C3→formation of MAC (amplification 2). Initiation of the alternative pathway (AP) occurs by spontaneous low-rate hydrolysis of the thioester in C3 and quickly spreads to nearby surfaces via nascent C3b, which binds covalently to a target. As an additional activation route, it has been suggested that soluble CL-12 in collaboration with properdin provides a platform for de novo C3 convertase assembly. All activation pathways consequently lead to opsonization, chemotaxis, inflammation and lysis against microbes or dying host cells.